Valuation: Damora Therapeutics, Inc.

Market Cap 1.28B 1.12B 1.06B 963M 1.8B 122B 1.82B 12.65B 4.9B 62.45B 4.79B 4.69B 201B P/E 2026 *
-10.3x
P/E 2027 * -9.94x
Enterprise Value 814M 714M 675M 615M 1.15B 78.01B 1.16B 8.07B 3.13B 39.85B 3.06B 2.99B 128B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
91.59%
Yield 2026 *
-
Yield 2027 * -
1 day+1.92%
1 week-8.54%
Current month-26.69%
1 month-32.53%
3 months-8.46%
6 months-17.52%
Current year-10.21%
1 week 19.39
Extreme 19.39
23.43
1 month 19.39
Extreme 19.39
31.11
Current year 16.5
Extreme 16.5001
34.89
1 year 3.5
Extreme 3.5
38.33
3 years 2.01
Extreme 2.01
38.33
5 years 2.01
Extreme 2.01
97.88
10 years 2.01
Extreme 2.01
449.75
Manager TitleAgeSince
Chief Executive Officer 55 30/03/2026
Director of Finance/CFO - 01/05/2026
Chief Tech/Sci/R&D Officer 60 05/01/2026
Director TitleAgeSince
Chairman 40 23/03/2026
Director/Board Member 42 10/11/2025
Director/Board Member 41 10/11/2025
Date Insider Type Main position Quantity % Market Cap. Importance
12/8/26 Free

Director

30,350 0.0493%
6/7/26 Sell

General Counsel

-245 0.0004%
1/5/26 Other

Chief Financial Officer

312,535 0.5077%
Change 5-day change 1-year change 3-year change Capi.($)
+1.92%-8.54%+364.27%+44.73% 1.28B
-0.14%+4.33%+9.88%+31.73% 47.97B
-1.69%+1.48%+53.02%+33.59% 44.5B
+2.56%+7.34%+382.17%+594.81% 43.93B
+0.24%+2.85%+9.78%+89.54% 41.03B
-0.62%-1.11%+4.70%+46.02% 29.85B
-0.28%+1.07%+26.83%+152.91% 17.27B
-0.46%+1.20%+26.78%+41.32% 15.3B
-2.21%-4.70% - - 14.82B
+3.37%+9.21%+9.93% - 15.34B
Average +0.27%+1.26%+98.60%+129.33% 27.13B
Weighted average by Cap. +0.12%+2.81%+84.43%+155.62%

Financials

2026 *2027 *
Net sales - -
Net income -126M -110M -104M -94.82M -178M -12.03B -179M -1.25B -482M -6.15B -471M -461M -19.76B -151M -133M -125M -114M -214M -14.5B -215M -1.5B -581M -7.41B -568M -556M -23.81B
Net Debt -462M -405M -383M -349M -653M -44.24B -657M -4.58B -1.77B -22.6B -1.73B -1.7B -72.64B -352M -309M -292M -266M -497M -33.72B -501M -3.49B -1.35B -17.22B -1.32B -1.29B -55.36B
Logo Damora Therapeutics, Inc.
Damora Therapeutics, Inc. is a biotechnology company that focuses on hematologic disorders. It is advancing a new generation of biologics to treat mutant calreticulin-driven myeloproliferative neoplasms (MPN), including essential thrombocythemia and myelofibrosis, where there is significant medical need for disease-modifying treatments. Its lead asset, DMR-001, is an investigational monoclonal antibody therapy targeting mutant calreticulin (mutCALR). It is developing candidates for treatment of essential thrombocythemia (ET), an MPN associated with the overproduction of platelets, and myelofibrosis, an MPN involving the overproliferation of blood cells and deposition of fibrous material in the bone marrow and spleen. DMR-002, an afucosylated antibody designed to enhance antibody-dependent cellular cytotoxicity and amplify natural immune killing of malignant cells. DMR-003, a bi-specific T-cell engager antibody designed to recruit and direct T-cell-mediated killing of malignant cells.
Employees
7
Date Price Change Volume
25/09/26 USD 20.66 +1.92% 1,431,821
24/09/26 USD 20.27 -0.83% 875,177
23/09/26 USD 20.44 -8.79% 1,067,227
22/09/26 USD 22.41 -1.93% 355,236
21/09/26 USD 22.85 +1.15% 618,453
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
20.66USD
Average target price
46.89USD
Spread / Average Target
+126.95%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. DMRA Stock